"Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety" [Response To Letter].
作者信息
Mascellino Maria Teresa, Di Timoteo Federica, De Angelis Massimiliano, Oliva Alessandra
机构信息
Department of Public Health and Infectious Diseases, Sapienza University, Rome, Lazio, Italy.
出版信息
Infect Drug Resist. 2021 Oct 28;14:4501-4502. doi: 10.2147/IDR.S344230. eCollection 2021.
Abstract
摘要
相似文献
1
"Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety" [Response To Letter].主要抗SARS-CoV-2疫苗概述：作用机制、疗效与安全性[对信件的回复]
Infect Drug Resist. 2021 Oct 28;14:4501-4502. doi: 10.2147/IDR.S344230. eCollection 2021.
2
Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety.主要抗SARS-CoV-2疫苗概述：作用机制、疗效与安全性
Infect Drug Resist. 2021 Aug 31;14:3459-3476. doi: 10.2147/IDR.S315727. eCollection 2021.
3
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
4
Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi.两种灭活严重急性呼吸综合征冠状病毒2疫苗加强接种对成人有症状的冠状病毒病感染的疗效和安全性：在阿布扎比进行的一项双盲、随机、安慰剂对照3期试验的结果
Vaccines (Basel). 2023 Jan 30;11(2):299. doi: 10.3390/vaccines11020299.
5
Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study.五种不同的新型冠状病毒2疫苗在病情缓解或疾病活动度低的自身免疫性风湿和肌肉骨骼疾病患者及健康对照中的体液和细胞免疫原性及安全性：一项单中心研究
Front Immunol. 2022 Mar 31;13:846248. doi: 10.3389/fimmu.2022.846248. eCollection 2022.
6
Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years.BNT162b2 信使 RNA COVID-19 疫苗与 5 岁以下儿童中其他获批疫苗的比较安全性。
JAMA Netw Open. 2022 Oct 3;5(10):e2237140. doi: 10.1001/jamanetworkopen.2022.37140.
7
Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.临床试验中 SARS-CoV-2 疫苗的免疫原性和安全性。
Front Biosci (Landmark Ed). 2021 Nov 30;26(11):1286-1304. doi: 10.52586/5024.
8
The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants.全球疫苗接种对 SARS-CoV-2 感染的影响：疫苗机制、临床试验结果、疫苗接种覆盖率以及与新型变异体相互作用的综述。
Curr Med Chem. 2022;29(15):2673-2690. doi: 10.2174/0929867328666210902094254.
9
Omicron, a new SARS-CoV-2 variant: assessing the impact on severity and vaccines efficacy.奥密克戎，一种新型严重急性呼吸综合征冠状病毒2变体：评估其对疾病严重程度和疫苗效力的影响。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2034458. doi: 10.1080/21645515.2022.2034458. Epub 2022 Mar 3.
10
The efficacy and safety of SARS-CoV-2 vaccines mRNA1273 and BNT162b2 might be complicated by rampant C-to-U RNA editing.SARS-CoV-2 疫苗 mRNA1273 和 BNT162b2 的疗效和安全性可能因猖獗的 C 到 U RNA 编辑而变得复杂。
J Appl Genet. 2023 May;64(2):361-365. doi: 10.1007/s13353-023-00756-w. Epub 2023 Mar 21.
引用本文的文献
1
Nanotoxicology: developments and new insights.纳米毒理学：进展与新见解
Nanomedicine (Lond). 2025 Jan;20(2):225-241. doi: 10.1080/17435889.2024.2443385. Epub 2024 Dec 26.
2
Prospects of Innovative Therapeutics in Combating the COVID-19 Pandemic.创新疗法抗击新冠疫情的前景
Mol Biotechnol. 2025 Jul;67(7):2598-2606. doi: 10.1007/s12033-024-01240-4. Epub 2024 Aug 1.
3
The Equal Neutralizing Effectiveness of BNT162b2, ChAdOx1 nCoV-19, and Sputnik V Vaccines in the Palestinian Population.BNT162b2、ChAdOx1 nCoV-19和卫星五号疫苗在巴勒斯坦人群中的中和效力相当
Vaccines (Basel). 2024 May 3;12(5):493. doi: 10.3390/vaccines12050493.
4
Comorbidities of COVID-19 Patients.COVID-19 患者的合并症。
Medicina (Kaunas). 2023 Jul 29;59(8):1393. doi: 10.3390/medicina59081393.
5
Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review.影响纳米粒子在生物医学应用中毒性的结构参数：综述
J Nanopart Res. 2023;25(3):43. doi: 10.1007/s11051-023-05690-w. Epub 2023 Feb 27.
6
Determining the Effect of COVID-19 on the Menstrual Cycle Among Women of Reproductive Age Group in the Jazan Region: A Cross-Sectional Study.确定新冠疫情对吉赞地区育龄妇女月经周期的影响：一项横断面研究
Cureus. 2022 Dec 12;14(12):e32431. doi: 10.7759/cureus.32431. eCollection 2022 Dec.
7
Mesenchymal stem cell therapy on top of triple therapy with remdesivir, dexamethasone, and tocilizumab improves PaO/FiO in severe COVID-19 pneumonia.在使用瑞德西韦、地塞米松和托珠单抗三联疗法基础上进行间充质干细胞治疗可改善重症 COVID-19 肺炎患者的氧合指数（PaO₂/FiO₂） 。
Front Med (Lausanne). 2022 Sep 23;9:1001979. doi: 10.3389/fmed.2022.1001979. eCollection 2022.
8
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).新型冠状病毒病（COVID-19）的现有药物和预防性疫苗概述。
Cell Mol Biol Lett. 2022 May 13;27(1):38. doi: 10.1186/s11658-022-00339-3.
9
Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review.辉瑞-生物科技新冠疫苗（BNT162b2）的副作用：一项系统综述
Cureus. 2022 Mar 26;14(3):e23526. doi: 10.7759/cureus.23526. eCollection 2022 Mar.
本文引用的文献
1
A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2.第三剂灭活疫苗可增强针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的回忆反应的效力、广度和持续时间。
Protein Cell. 2024 Dec 2;15(12):930-937. doi: 10.1093/procel/pwae033.
2
Sinopharm! An Unavoidable Contender in the Struggle Against COVID [Letter].国药集团！抗击新冠疫情中不可避免的竞争者[信函]
Infect Drug Resist. 2021 Sep 22;14:3899-3900. doi: 10.2147/IDR.S338460. eCollection 2021.
3
Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety.主要抗SARS-CoV-2疫苗概述：作用机制、疗效与安全性
Infect Drug Resist. 2021 Aug 31;14:3459-3476. doi: 10.2147/IDR.S315727. eCollection 2021.
4
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.2 种灭活 SARS-CoV-2 疫苗对成人有症状 COVID-19 感染的效果：一项随机临床试验。
JAMA. 2021 Jul 6;326(1):35-45. doi: 10.1001/jama.2021.8565.
Zotero 插件